Optimizing Care in Inflammatory Bowel Disease (IBD): The Role of Emerging Therapies in Improving Patient Outcomes

Released On
June 30, 2022

Expires On
June 30, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Gastroenterology, Primary Care

Topic(s)
IBD, Inflammatory bowel disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from AbbVie.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward gastroenterologists, primary care clinicians, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with IBD.

Activity Overview

Although biologic agents helped usher in a new treatment paradigm for inflammatory bowel disease (IBD), appreciable rates of primary non-response, loss of response, and adverse reactions still require additional treatments. Clinical research has therefore focused on new therapeutic targets and modifications of existing ones to improve the response rates and safety/tolerability profile of IBD medications. Research has resulted in the development of small molecule drugs (SMDs) like selective JAK inhibitors and leukocyte trafficking/migrating inhibitors, and their emergence has created a need for educational activities that help clinicians navigate the ever-expanding clinical armamentarium.

This educational activity is an archive of the live symposium held on May 21, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply diagnostic criteria/algorithms toward an early diagnosis of IBD based on patient presentation
  • Select an approved therapy targeting IBD based on current clinical evidence and guidelines
  • Evaluate efficacy and safety of emerging therapies in the multimodal treatment approach to IBD
  • Develop collaborative multidisciplinary management strategies for long-term management of IBD

 

Faculty

FACULTY_NAME

Anita Afzali, MD, MPH, MHCM

Professor of Medicine
Executive Vice Chair for Clinical Operations
Department of Internal Medicine
University of Cincinnati College of Medicine
Associate Chief Medical Officer
UC Health
Cincinnati, OH

FACULTY_NAME

Marla C. Dubinsky, MD

Professor of Medicine, Gastroenterology, and Pediatrics
Icahn School of Medicine at Mount Sinai
Chief, Division of Pediatric Gastroenterology
Mount Sinai Kravis Children’s Hospital
Co-Director, Susan and Leonard Feinstein Inflammatory Bowel Disease Center
Mount Sinai
New York, NY

FACULTY_NAME

Christina Ha, MD, FACG, AGAF

Associate Professor of Medicine
F. Widjaja Foundation
Inflammatory Bowel and Immunobiology Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA


Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Anita Afzali, MD, MPH, MHCM
  • Grant/Research Support: AbbVie, Takeda, Janssen, Bristol Myers Squibb
  • Consultant: AbbVie, Takeda, Janssen, Celgene, Pfizer
  • Speaker’s Bureau: AbbVie, Takeda, Janssen, Celgene, Pfizer
  • Other: IBD Horizons
Marla C. Dubinsky, MD
  • Grant/Research Support: AbbVie, Janssen Global Services LLC, Pfizer, Prometheus Labs
  • Consultant: AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Roche, Genentech, Gilead, Janssen Global Services LLC, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals USA, UCB SA
  • Stock/Shareholder: Trellus Health Inc
  • Other: Licensing Fee: Takeda Pharmaceuticals USA
Christina Ha, MD, FACG, AGAF
  • Grant/Research Support: Pfizer
  • Consultant: AbbVie
  • Advisory Board: AbbVie, InDex Pharmaceuticals, Janssen, Genentech, Pfizer, Takeda, Bristol Myers Squibb
  • Speaker’s Bureau: AbbVie

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.